Index - P/E 23.93 EPS (ttm) 4.60 Insider Own 3.34% Shs Outstand 62.26M Perf Week 0.50%
Market Cap 6.94B Forward P/E 5.29 EPS next Y 20.79 Insider Trans 0.36% Shs Float 60.93M Perf Month -4.51%
Income 330.79M PEG 5.32 EPS next Q 4.76 Inst Own 91.58% Short Float 6.08% Perf Quarter -10.49%
Sales 3.84B P/S 1.80 EPS this Y 1.49% Inst Trans -0.76% Short Ratio 5.95 Perf Half Y -13.61%
Book/sh 58.65 P/B 1.88 EPS next Y 12.02% ROA 2.96% Short Interest 3.70M Perf Year -19.48%
Cash/sh 28.84 P/C 3.81 EPS next 5Y 4.50% ROE 9.41% 52W Range 103.01 - 146.70 Perf YTD -10.56%
Dividend Est. - P/FCF 6.86 EPS past 5Y -3.53% ROI 3.73% 52W High -25.01% Beta 0.64
Dividend TTM - Quick Ratio 1.78 Sales past 5Y 15.52% Gross Margin 73.55% 52W Low 6.80% ATR (14) 3.05
Dividend Ex-Date - Current Ratio 2.15 EPS Y/Y TTM 310.66% Oper. Margin 15.83% RSI (14) 42.69 Volatility 3.82% 2.53%
Employees 2800 Debt/Eq 1.57 Sales Y/Y TTM 2.81% Profit Margin 8.61% Recom 1.55 Target Price 181.01
Option/Short Yes / Yes LT Debt/Eq 1.40 EPS Q/Q -124.85% Payout 0.00% Rel Volume 1.11 Prev Close 109.29
Sales Surprise -5.45% EPS Surprise -35.87% Sales Q/Q 1.03% Earnings May 01 AMC Avg Volume 622.41K Price 110.01
SMA20 -0.67% SMA50 -6.01% SMA200 -12.11% Trades
Volume 693,768 Change 0.66%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-03-24 Initiated Robert W. Baird
Outperform
$160
Nov-27-23 Downgrade UBS
Buy → Neutral
$170 → $135
Sep-29-23 Initiated Raymond James
Mkt Perform
Jun-12-23 Resumed Wells Fargo
Equal Weight
$184 → $140
Dec-09-22 Upgrade Goldman
Neutral → Buy
$192 → $190
Jun-14-22 Initiated UBS
Buy
$194
Apr-06-22 Downgrade Goldman
Buy → Neutral
$202 → $196
Nov-19-21 Resumed Goldman
Buy
$198
Oct-07-21 Resumed Jefferies
Buy
$172
Oct-05-21 Initiated Citigroup
Buy
$200
Sep-23-21 Initiated Needham
Buy
$220
May-19-21 Resumed JP Morgan
Overweight
$183 → $206
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$186
Feb-05-21 Reiterated H.C. Wainwright
Buy
$195 → $207
Feb-03-21 Upgrade Piper Sandler
Neutral → Overweight
$150 → $175
Jan-29-21 Downgrade Morgan Stanley
Overweight → Equal-Weight
Dec-16-20 Initiated UBS
Buy
$174
Nov-03-20 Reiterated H.C. Wainwright
Buy
$185 → $195
Oct-09-20 Reiterated H.C. Wainwright
Buy
$175 → $185
Sep-14-20 Resumed JP Morgan
Overweight
$175
Show Previous Ratings
May-03-24 12:41PM
11:49AM
May-02-24 11:26AM
03:53AM
May-01-24 08:56PM
07:00PM
Loading…
07:00PM
04:24PM
(Associated Press Finance)
04:10PM
04:05PM
Apr-30-24 09:50AM
Apr-24-24 04:05PM
10:01AM
05:21AM
Apr-23-24 11:15AM
Apr-17-24 04:15PM
07:45AM
Loading…
Apr-10-24 07:45AM
Apr-04-24 09:15AM
Apr-02-24 07:30AM
Mar-29-24 11:30AM
Mar-28-24 10:15AM
Mar-20-24 10:15AM
Mar-18-24 03:28PM
Mar-17-24 08:50AM
Mar-14-24 12:00PM
10:00AM
Mar-13-24 02:25PM
Mar-12-24 05:34PM
04:15PM
Mar-09-24 11:15AM
Mar-07-24 01:51PM
01:10PM
Loading…
01:10PM
(Thomson Reuters StreetEvents)
10:08AM
Feb-29-24 10:45AM
10:35AM
Feb-28-24 06:30PM
05:20PM
04:33PM
04:29PM
(Associated Press Finance)
04:05PM
Feb-27-24 10:15PM
(Thomson Reuters StreetEvents)
07:45AM
Feb-24-24 05:06AM
Feb-23-24 09:15AM
Feb-21-24 08:50AM
(The Wall Street Journal)
07:45AM
Feb-20-24 05:00PM
04:15PM
Feb-14-24 04:15PM
Feb-13-24 10:15AM
Feb-09-24 09:15AM
Feb-07-24 07:35AM
02:00AM
Feb-03-24 05:06AM
Jan-31-24 03:33PM
12:03PM
Jan-22-24 05:16AM
Jan-18-24 05:37AM
Jan-13-24 05:06AM
Dec-28-23 10:06PM
Dec-22-23 12:07PM
11:16AM
Dec-21-23 04:17PM
04:09PM
04:05PM
Dec-20-23 04:15PM
05:21AM
Dec-08-23 01:20PM
11:30AM
09:15AM
Dec-01-23 09:02AM
Nov-30-23 07:45AM
Nov-29-23 11:15AM
Nov-28-23 08:48AM
Nov-27-23 09:49AM
Nov-15-23 05:21AM
Nov-14-23 12:50PM
02:00AM
Nov-09-23 05:07PM
Nov-08-23 07:00PM
05:52PM
04:42PM
(Associated Press Finance)
04:05PM
Nov-07-23 12:33PM
07:45AM
Nov-01-23 04:15PM
10:01AM
Oct-31-23 05:42PM
Oct-30-23 04:05PM
Oct-26-23 11:40AM
Oct-25-23 04:15PM
08:34AM
08:30AM
Oct-23-23 07:45AM
Oct-21-23 06:38AM
Oct-20-23 10:30AM
Oct-18-23 07:55AM
07:45AM
Oct-17-23 09:55AM
04:21AM
Oct-16-23 07:45AM
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Carr Patricia SVP, Chief Accounting Officer Mar 07 '24 Sale 116.98 1,768 206,821 6,596 Mar 08 06:07 PM Carr Patricia SVP, Chief Accounting Officer Mar 06 '24 Sale 119.64 1,936 231,628 8,364 Mar 08 06:07 PM Johnson Philip L EVP & Chief Financial Officer Mar 01 '24 Buy 119.65 12,000 1,435,800 27,932 Mar 05 07:28 PM Cook Jennifer E. Director Dec 04 '23 Sale 119.27 417 49,736 6,888 Dec 06 04:31 PM Smith Mark Douglas Director Dec 04 '23 Sale 119.27 417 49,736 6,888 Dec 06 04:39 PM Patil Neena M EVP & Chief Legal Officer Sep 01 '23 Sale 144.25 1,500 216,375 29,186 Sep 06 05:09 PM Carr Patricia SVP, Chief Accounting Officer Aug 29 '23 Sale 143.47 142 20,373 5,986 Aug 31 06:44 PM Patil Neena M EVP & Chief Legal Officer Aug 15 '23 Sale 139.59 750 104,695 30,686 Aug 17 05:21 PM McSharry Heather Ann Director Aug 14 '23 Sale 138.16 1,344 185,685 16,778 Aug 15 05:52 PM Sohn Catherine A. Director Aug 14 '23 Sale 138.16 1,241 171,455 14,868 Aug 15 06:02 PM ENRIGHT PATRICK G Director Aug 14 '23 Sale 138.16 1,241 171,455 20,946 Aug 15 05:45 PM O'Keefe Kenneth W Director Aug 14 '23 Sale 138.16 1,241 171,455 24,723 Aug 15 07:49 PM Winningham Rick E Director Aug 14 '23 Sale 138.16 1,241 171,455 10,444 Aug 15 06:08 PM Gray Peter Director Aug 14 '23 Sale 138.16 1,241 171,455 16,068 Aug 15 05:47 PM Cook Jennifer E. Director Aug 14 '23 Sale 138.16 1,241 171,454 7,305 Aug 15 05:44 PM RIEDEL NORBERT G Director Aug 14 '23 Sale 138.16 1,241 171,454 13,705 Aug 15 05:58 PM ORiordan Anne Director Aug 14 '23 Sale 138.16 1,241 171,454 12,551 Aug 15 07:51 PM Smith Mark Douglas Director Aug 14 '23 Sale 138.16 1,241 171,454 7,305 Aug 15 06:00 PM Carr Patricia SVP, Chief Accounting Officer Aug 14 '23 Sale 138.16 158 21,829 6,128 Aug 15 05:43 PM Mulligan Seamus Director Jun 08 '23 Option Exercise 81.76 4,500 367,920 1,169,300 Jun 12 04:47 PM Carr Patricia SVP, Chief Accounting Officer Jun 07 '23 Sale 127.92 126 16,117 6,286 Jun 09 04:55 PM Patil Neena M EVP & Chief Legal Officer Jun 01 '23 Sale 127.98 1,600 204,763 32,826 Jun 05 08:24 PM GALA RENEE D EVP & Chief Financial Officer May 18 '23 Sale 131.75 6,000 790,474 35,978 May 19 08:45 PM
Index RUT P/E - EPS (ttm) -2.53 Insider Own 6.08% Shs Outstand 56.35M Perf Week 8.30%
Market Cap 1.26B Forward P/E - EPS next Y -1.26 Insider Trans -7.86% Shs Float 52.96M Perf Month 0.27%
Income -136.88M PEG - EPS next Q -0.48 Inst Own 93.61% Short Float 4.36% Perf Quarter -16.44%
Sales 356.30M P/S 3.53 EPS this Y 36.49% Inst Trans -5.41% Short Ratio 4.68 Perf Half Y 61.86%
Book/sh 4.46 P/B 5.00 EPS next Y 21.06% ROA -36.87% Short Interest 2.31M Perf Year -28.58%
Cash/sh 1.55 P/C 14.38 EPS next 5Y - ROE -50.77% 52W Range 12.05 - 34.98 Perf YTD -3.59%
Dividend Est. - P/FCF - EPS past 5Y -15.39% ROI -53.27% 52W High -36.19% Beta 0.95
Dividend TTM - Quick Ratio 1.77 Sales past 5Y 29.21% Gross Margin 56.53% 52W Low 85.23% ATR (14) 1.10
Dividend Ex-Date - Current Ratio 1.77 EPS Y/Y TTM 24.84% Oper. Margin -37.63% RSI (14) 49.56 Volatility 4.61% 4.77%
Employees 1438 Debt/Eq 0.05 Sales Y/Y TTM 26.84% Profit Margin -38.42% Recom 1.29 Target Price 30.12
Option/Short Yes / Yes LT Debt/Eq 0.02 EPS Q/Q 21.89% Payout - Rel Volume 1.07 Prev Close 22.26
Sales Surprise 1.59% EPS Surprise 0.21% Sales Q/Q 24.05% Earnings May 30 AMC Avg Volume 493.80K Price 22.32
SMA20 0.15% SMA50 -4.25% SMA200 -0.52% Trades
Volume 526,002 Change 0.27%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-26-24 Initiated Truist
Buy
$35
Jan-17-24 Upgrade DA Davidson
Neutral → Buy
$30 → $32
Jan-03-24 Initiated Barclays
Overweight
$29
Apr-12-23 Initiated Stephens
Overweight
$37
Jan-04-23 Reiterated Needham
Buy
$35 → $40
Dec-13-22 Upgrade Citigroup
Neutral → Buy
$40
Dec-09-22 Upgrade SVB Leerink
Mkt Perform → Outperform
$31 → $34
Oct-13-22 Initiated DA Davidson
Neutral
$25
Sep-16-22 Initiated KeyBanc Capital Markets
Overweight
$40
Apr-14-22 Initiated Guggenheim
Buy
$45
Jan-06-22 Downgrade SVB Leerink
Outperform → Mkt Perform
$57 → $41
Dec-02-21 Initiated Jefferies
Buy
$70
Sep-02-21 Reiterated Needham
Buy
$70 → $81
Aug-27-21 Initiated Canaccord Genuity
Buy
$81
Jul-13-21 Initiated JMP Securities
Mkt Outperform
$80
Jun-08-21 Initiated Berenberg
Buy
$70
Apr-29-21 Resumed JP Morgan
Overweight
$64
Apr-01-21 Initiated Robert W. Baird
Outperform
$60
Nov-11-20 Initiated Stephens
Overweight
$50
Oct-27-20 Initiated Needham
Buy
$44
Show Previous Ratings
May-01-24 06:46AM
Apr-29-24 06:48AM
Mar-25-24 07:01PM
Mar-19-24 06:48AM
Mar-17-24 10:22AM
06:56AM
Loading…
Mar-15-24 06:56AM
(Thomson Reuters StreetEvents)
Mar-14-24 08:55PM
06:00PM
05:25PM
04:22PM
(Associated Press Finance)
04:03PM
Mar-07-24 10:00AM
Feb-27-24 04:05PM
Feb-20-24 06:48AM
Feb-19-24 11:53AM
04:05PM
Loading…
Feb-05-24 04:05PM
06:54AM
Jan-23-24 06:40AM
Jan-18-24 07:59PM
Jan-16-24 04:05PM
Jan-11-24 06:44AM
Dec-27-23 09:55AM
08:06AM
Dec-11-23 09:55AM
Dec-08-23 08:21AM
Dec-06-23 10:37AM
(Thomson Reuters StreetEvents) +21.22%
Dec-05-23 06:00PM
05:40PM
05:15PM
04:17PM
(Associated Press Finance)
04:03PM
Loading…
04:03PM
Dec-01-23 06:00AM
Nov-16-23 03:12AM
Nov-08-23 06:00AM
Nov-01-23 09:12AM
06:03AM
Sep-15-23 10:01PM
Sep-14-23 09:39PM
Sep-11-23 12:11PM
Sep-07-23 12:08PM
11:45AM
09:30AM
09:00AM
07:37AM
(Thomson Reuters StreetEvents)
Sep-06-23 05:15PM
04:07PM
04:03PM
Sep-04-23 12:00PM
09:55AM
08:39AM
Aug-31-23 08:40AM
Aug-16-23 12:58PM
Aug-15-23 05:11PM
Aug-14-23 04:03PM
Aug-07-23 06:50PM
Aug-01-23 06:03AM
Jul-20-23 08:40PM
Jul-14-23 04:48PM
Jul-13-23 04:03PM
Jul-11-23 12:00PM
Jun-13-23 06:43AM
May-31-23 06:30PM
05:15PM
04:08PM
04:03PM
May-17-23 04:03PM
May-16-23 04:05PM
May-15-23 05:45PM
May-11-23 05:35PM
May-09-23 05:35PM
May-07-23 08:06AM
May-04-23 08:25AM
May-02-23 05:15PM
Apr-25-23 04:04PM
Mar-29-23 04:03PM
Mar-27-23 11:33AM
06:21AM
Mar-23-23 07:24AM
(Thomson Reuters StreetEvents) -7.74%
Mar-22-23 05:15PM
04:03PM
04:03PM
Mar-20-23 04:04PM
Mar-18-23 04:32PM
Mar-17-23 06:50AM
Mar-15-23 04:05PM
Mar-08-23 06:45PM
Feb-27-23 10:34AM
09:31AM
09:27AM
Feb-14-23 12:00PM
Feb-03-23 08:41AM
Feb-02-23 06:38AM
Jan-31-23 04:03PM
Jan-26-23 06:45AM
Jan-20-23 05:18PM
Jan-04-23 02:25PM
Dec-14-22 11:20AM
Dec-10-22 08:03AM
Dec-08-22 05:15PM
04:03PM
Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in Wilmington, DE.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gunzburg Janet Principal Accounting Officer May 01 '24 Sale 21.00 286 6,006 34,934 May 02 04:22 PM Gunzburg Janet Principal Accounting Officer Apr 18 '24 Sale 22.85 912 20,836 35,220 Apr 19 04:24 PM Linetsky David SVP, Life Sciences Apr 18 '24 Sale 22.85 269 6,146 7,087 Apr 19 04:24 PM Indig Chaim Chief Executive Officer Apr 15 '24 Sale 22.86 3,392 77,532 1,222,005 Apr 17 04:07 PM Linetsky David SVP, Life Sciences Apr 15 '24 Sale 22.86 2,212 50,561 204,038 Apr 17 04:13 PM Roberts Evan Chief Operating Officer Apr 15 '24 Sale 22.86 2,029 46,378 754,903 Apr 17 04:13 PM Hoffman Allison C General Counsel & Secretary Apr 15 '24 Sale 22.86 1,238 28,297 135,621 Apr 17 04:10 PM Gandhi Balaji Chief Financial Officer Apr 15 '24 Sale 22.86 948 21,669 97,230 Apr 17 04:08 PM VanDuyn Amy Beth SVP, Human Resources Apr 15 '24 Sale 22.86 685 15,657 119,010 Apr 17 04:13 PM Gunzburg Janet Principal Accounting Officer Apr 10 '24 Sale 23.10 2,768 63,928 36,132 Apr 12 06:40 PM Roberts Evan Chief Operating Officer Apr 09 '24 Option Exercise 2.03 23,330 47,360 756,932 Apr 10 05:18 PM Hoffman Allison C General Counsel & Secretary Apr 09 '24 Sale 23.42 4,626 108,360 136,859 Apr 10 05:20 PM VanDuyn Amy Beth SVP, Human Resources Apr 09 '24 Sale 23.43 3,768 88,277 119,695 Apr 10 05:19 PM Indig Chaim Chief Executive Officer Apr 08 '24 Sale 22.62 12,043 272,414 1,225,397 Apr 10 05:19 PM Gandhi Balaji Chief Financial Officer Apr 08 '24 Sale 22.62 7,778 175,939 98,178 Apr 10 05:19 PM Roberts Evan Chief Operating Officer Apr 08 '24 Sale 22.62 7,178 162,367 733,602 Apr 10 05:18 PM Hoffman Allison C General Counsel & Secretary Apr 08 '24 Sale 22.62 5,549 125,519 141,485 Apr 10 05:20 PM Linetsky David SVP, Life Sciences Apr 08 '24 Sale 22.62 3,914 88,535 206,250 Apr 10 05:18 PM VanDuyn Amy Beth SVP, Human Resources Apr 08 '24 Sale 22.62 3,354 75,868 123,463 Apr 10 05:19 PM Gunzburg Janet Principal Accounting Officer Apr 08 '24 Sale 22.62 1,709 38,658 38,900 Apr 10 05:18 PM Linetsky David SVP, Life Sciences Apr 08 '24 Sale 22.62 247 5,587 7,356 Apr 10 05:18 PM Gandhi Balaji Chief Financial Officer Mar 25 '24 Sale 23.21 3,504 81,332 94,030 Mar 27 04:06 PM Roberts Evan Chief Operating Officer Mar 21 '24 Sale 23.52 25,962 610,684 728,570 Mar 25 04:16 PM Gunzburg Janet Principal Accounting Officer Mar 20 '24 Sale 23.66 137 3,241 38,949 Mar 21 04:11 PM Linetsky David SVP, Life Sciences Mar 20 '24 Sale 23.66 30 710 7,095 Mar 21 04:11 PM Gunzburg Janet Principal Accounting Officer Mar 19 '24 Sale 23.27 2,817 65,561 40,609 Apr 10 05:18 PM Linetsky David SVP, Life Sciences Mar 19 '24 Sale 23.27 402 9,356 7,125 Mar 20 04:21 PM Linetsky David SVP, Life Sciences Mar 18 '24 Sale 22.22 46 1,022 7,527 Mar 20 04:21 PM Gunzburg Janet Principal Accounting Officer Feb 09 '24 Sale 28.00 480 13,440 39,086 Feb 13 04:58 PM Gunzburg Janet Principal Accounting Officer Feb 02 '24 Sale 27.00 480 12,960 39,566 Feb 06 04:22 PM Gunzburg Janet Principal Accounting Officer Feb 01 '24 Sale 25.99 328 8,525 40,046 Feb 02 06:06 PM Indig Chaim Chief Executive Officer Jan 17 '24 Sale 24.12 63,931 1,542,118 1,216,479 Jan 18 04:51 PM Roberts Evan Chief Operating Officer Jan 17 '24 Sale 24.12 41,081 990,939 754,532 Jan 18 04:52 PM Linetsky David SVP, Life Sciences Jan 17 '24 Sale 24.12 30,659 739,544 204,059 Jan 18 04:52 PM Davidoff Michael J. SVP, Payer Business Jan 17 '24 Sale 24.12 17,677 426,398 73,391 Jan 18 04:53 PM VanDuyn Amy Beth SVP, Human Resources Jan 17 '24 Sale 24.12 10,213 246,354 119,695 Jan 18 04:53 PM Gandhi Balaji Chief Financial Officer Jan 17 '24 Sale 24.12 9,192 221,726 97,534 Jan 18 04:53 PM Hoffman Allison C General Counsel & Secretary Jan 17 '24 Sale 24.12 7,605 183,445 136,859 Jan 18 04:52 PM Indig Chaim Chief Executive Officer Jan 16 '24 Sale 24.55 3,586 88,020 1,280,410 Jan 18 04:51 PM Linetsky David SVP, Life Sciences Jan 16 '24 Sale 24.55 2,318 56,896 234,718 Jan 18 04:52 PM Roberts Evan Chief Operating Officer Jan 16 '24 Sale 24.55 2,247 55,154 795,613 Jan 18 04:52 PM Hoffman Allison C General Counsel & Secretary Jan 16 '24 Sale 24.55 1,316 32,302 144,464 Jan 18 04:52 PM Davidoff Michael J. SVP, Payer Business Jan 16 '24 Sale 24.55 1,310 32,155 91,068 Jan 18 04:53 PM Gandhi Balaji Chief Financial Officer Jan 16 '24 Sale 24.55 932 22,876 106,726 Jan 18 04:53 PM VanDuyn Amy Beth SVP, Human Resources Jan 16 '24 Sale 24.55 738 18,115 129,908 Jan 18 04:53 PM Gunzburg Janet Principal Accounting Officer Jan 12 '24 Sale 24.11 205 4,943 40,374 Feb 02 06:06 PM Gunzburg Janet Principal Accounting Officer Dec 19 '23 Sale 23.72 118 2,799 40,579 Dec 20 04:14 PM Linetsky David SVP, Life Sciences Dec 19 '23 Sale 23.72 25 593 7,573 Dec 20 04:13 PM Linetsky David SVP, Life Sciences Dec 18 '23 Sale 23.15 234 5,418 7,598 Dec 20 04:13 PM Gunzburg Janet Principal Accounting Officer Nov 01 '23 Sale 13.38 298 3,988 40,697 Nov 02 04:39 PM Roberts Evan Chief Operating Officer Oct 31 '23 Option Exercise 2.03 30,000 60,900 775,860 Nov 02 04:36 PM Indig Chaim Chief Executive Officer Oct 16 '23 Sale 16.61 3,295 54,727 1,241,996 Oct 17 06:08 PM Linetsky David SVP, Life Sciences Oct 16 '23 Sale 16.61 2,078 34,514 215,036 Oct 17 06:11 PM Roberts Evan Chief Operating Officer Oct 16 '23 Sale 16.61 1,971 32,736 745,860 Oct 17 06:14 PM Hoffman Allison C General Counsel & Secretary Oct 16 '23 Sale 16.61 1,297 21,542 115,025 Oct 17 06:15 PM Davidoff Michael J. SVP, Payer Business Oct 16 '23 Sale 16.61 1,198 19,898 92,378 Oct 17 06:22 PM Gandhi Balaji Chief Financial Officer Oct 16 '23 Sale 16.61 861 14,300 85,658 Oct 17 06:19 PM VanDuyn Amy Beth SVP, Human Resources Oct 16 '23 Sale 16.61 665 11,045 118,146 Oct 17 06:17 PM Linetsky David SVP, Life Sciences Sep 18 '23 Sale 19.67 130 2,557 7,832 Sep 20 04:17 PM Gunzburg Janet Principal Accounting Officer Sep 18 '23 Sale 19.79 125 2,474 40,995 Sep 20 04:23 PM Davidoff Michael J. SVP, Payer Business Sep 14 '23 Sale 20.16 2,953 59,537 93,576 Sep 14 05:07 PM Hoffman Allison C General Counsel & Secretary Sep 14 '23 Sale 20.17 2,210 44,566 116,322 Sep 14 05:14 PM VanDuyn Amy Beth SVP, Human Resources Sep 14 '23 Sale 20.16 2,000 40,316 118,811 Sep 14 05:12 PM Indig Chaim Chief Executive Officer Sep 13 '23 Sale 20.34 6,555 133,323 1,245,291 Sep 14 05:06 PM Gandhi Balaji Chief Financial Officer Sep 13 '23 Sale 20.34 3,957 80,482 86,519 Sep 14 05:08 PM Roberts Evan Chief Operating Officer Sep 13 '23 Sale 20.34 3,907 79,465 747,831 Sep 14 05:16 PM Davidoff Michael J. SVP, Payer Business Sep 13 '23 Sale 20.34 3,606 73,343 96,529 Sep 14 05:07 PM Hoffman Allison C General Counsel & Secretary Sep 13 '23 Sale 20.34 3,256 66,224 118,532 Sep 14 05:14 PM Linetsky David SVP, Life Sciences Sep 13 '23 Sale 20.34 2,059 41,878 217,114 Sep 14 05:04 PM VanDuyn Amy Beth SVP, Human Resources Sep 13 '23 Sale 20.34 1,826 37,139 120,811 Sep 14 05:12 PM Gunzburg Janet Principal Accounting Officer Sep 13 '23 Sale 20.34 934 18,996 41,120 Sep 14 05:09 PM Linetsky David SVP, Life Sciences Sep 13 '23 Sale 20.34 119 2,421 7,962 Sep 14 05:04 PM Linetsky David SVP, Life Sciences Sep 12 '23 Option Exercise 6.30 11,853 74,715 219,173 Sep 14 05:04 PM Roberts Evan Chief Operating Officer Sep 08 '23 Option Exercise 2.03 30,000 60,900 745,179 Sep 11 04:25 PM Davidoff Michael J. SVP, Payer Business Jul 21 '23 Sale 31.75 1,075 34,131 93,576 Jul 25 04:28 PM Munson Gillian Director May 10 '23 Sale 30.06 3,555 106,864 19,315 May 11 04:48 PM Indig Chaim Chief Executive Officer May 09 '23 Option Exercise 8.03 12,453 99,998 1,243,675 May 11 04:42 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
